Please login to the form below

Not currently logged in

idiopathic pulmonary fibrosis

This page shows the latest idiopathic pulmonary fibrosis news and features for those working in and with pharma, biotech and healthcare.

Fishawack acquires brand communications agency Healthcircle

Fishawack acquires brand communications agency Healthcircle

Healthcircle has also worked on a variety of campaigns in the areas of oncology, idiopathic pulmonary fibrosis and consumer health to name a few.

Latest news

More from news
Approximately 5 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Ark has in-licensed the global rights to the phase 1. idiopathic pulmonary fibrosis programme. ... the phase 1 product AK3280 (GDC3280) for the treatment of idiopathic pulmonary fibrosis.

  • Getting multichannel marketing right Getting multichannel marketing right

    In recent years, Merck has run an animated video to raise awareness of thyroid disorders, Roche has recorded a choir made up of families affected by idiopathic pulmonary fibrosis and AstraZeneca

  • Deal Watch June 2016 Deal Watch June 2016

    pulmonary fibrosis (IPF) with cough. ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219, oral P2X3 antagonist for chronic cough (p2b) and idiopathic pulmonary fibrosis (p2) with cough, and other compounds.

  • Pharma deals in August 2015 Pharma deals in August 2015

    PRM 151 is under development for the treatment of idiopathic pulmonary fibrosis. ... Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐2 protein for idiopathic pulmonary fibrosis and myelofibrosis.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma. ... Company acquisition. 840. Galecto Biotech / BMS. TD139 galectin-3 inhibitor for Idiopathic pulmonary fibrosis.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Innovation and technology at Roche’s “Air Spain” Event

    The event Air Spain organised by Roche, spoke about how to  optimise research, knowledge and treatment of idiopathic pulmonary fibrosis.

  • Understanding the "Big Picture"

    For example, a technology originally intended to monitor the presence of lung fibrosis in idiopathic pulmonary fibrosis (IPF) but then finding utility in other fibrotic lung diseases. ... Keeping with the example of fibrosis, if the targets are viable,

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...